Pharmafile Logo
Pharmafocus logo
Advanced Search

NSCLC

Showing 15 posts of 133 posts found.

Cyramza image

Lilly’s lung cancer drug sees FDA approval

December 17, 2014
Sales and Marketing BMS, Cancer, FDA, NSCLC, cyramza, docetaxel, lilly, opdivo, ramucirumab

Eli Lilly’s lung cancer drug Cyramza (ramucirumab) has been shown the green light by the US Food and Drug Administration …

News
BI image

Boehringer’s lung cancer drug Vargatef sees EU approval

November 28, 2014
Sales and Marketing Boehringer, EU, Europe, IPF, NSCLC, lung cancer, nintedanib, ofev, vargatef

Boehringer Ingelheim’s nintedanib has received its second nod in Europe this month with the European Commission approving it for the …

News
BMS image

BMS lung cancer drug scores in Phase II

October 31, 2014
Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, FDA, NSCLC, bristol myers-squibb, odivo

Bristol-Myers Squibb is still in the hunt to gain significant market share in the PD-1 therapeutic vaccine race after releasing …

News
Boehringer image

Boehringer seeks more indications for IPF drug

October 22, 2014
Research and Development, Sales and Marketing Boehringer, IPF, NSCLC, colectoral, crc, nintedanib, ofev

Boehringer Ingelheim’s nintedanib has entered Phase III studies for the treatment of colorectal cancer (CRC), which could add to the …

News
Pfizer Xalkori

US rivals Pfizer and Merck team up for lung cancer

August 27, 2014
Medical Communications, Research and Development, Sales and Marketing Merck, NSCLC, Roche, Xalkori, melanoma, pembrolizumab

The two biggest rival US pharma firms have joined forces to help develop a new combination treatment for certain non-small …

News
Roche image

Roche lung cancer drug sees first approval

July 4, 2014
Sales and Marketing ALK+, Cancer, NSCLC, Pfizer, Roche, Xalkori, alectinib, alk, zykadia

Roche has seen the first approval for its new lung cancer drug alectinib in Japan as it looks to compete …

News
boehringer image

Boehringer lung cancer drug shows survival benefit

June 3, 2014
Sales and Marketing ASCO, Boehringer, NSCLC, afatinib, giotrif, lung cancer

A new analysis of two late-stage trials shows that Boehringer drug Giotrif extends overall survival in a large proportion of …

News
AZ image

AstraZeneca lung cancer data reveals promise

May 15, 2014
Sales and Marketing ASCO, AstraZeneca, NSCLC, azd0291, lung cancer

AstraZeneca has released promising data in a lung cancer trial with one of its investigational drugs, AZD9291, which has breakthrough …

News
astrazeneca_plaque

AstraZeneca begins lung cancer trial

May 9, 2014
Research and Development, Sales and Marketing AstraZeneca, Cancer, MEDI4736, NSCLC, lung cancer

AstraZeneca, currently at the centre of a £63 billion bid from US giant Pfizer, has begun a late-stage trial of …

News
GSK image

Lung cancer vaccine dropped

April 2, 2014
Research and Development, Sales and Marketing GSK, MAGE-A3, NSCLC, Vaccine, lung cancer, magrit

GlaxoSmithKline took a hit today after its lung cancer vaccine MAGE-A3 failed to benefit patients. The London-based firm has now …

News
Xalkori image

Pfizer’s Xalkori impresses in new setting

March 26, 2014
Research and Development, Sales and Marketing NHS, NICE, NSCLC, Pfizer, Xalkori, lung cancer

Pfizer’s lung cancer treatment Xalkori has proven better at treating patients in a first-line setting when compared to chemotherapy. This …

News
MSD image

Endocyte lung cancer drug shows promise

March 24, 2014
Research and Development, Sales and Marketing Endocyte, MSD, NSCLC, lung cancer, vintafolide

Endocyte and partner MSD have released positive mid-stage trial results for their investigational lung cancer drug vintafolide. The treatment met …

News
GSK image

GSK cancer vaccine fails again

March 20, 2014
Sales and Marketing Cancer, GSK, MAGE-A3 cancer immunotherapeutic, NSCLC, lung cancer, melanoma

GlaxoSmithKline’s MAGE-A3 cancer immunotherapeutic has delivered another late-stage blow to the firm but it still vows to continue trials.  The …

News

Boehringer’s first cancer drug gains NICE yes

March 17, 2014
Sales and Marketing Boehringer, Cancer, NICE, NSCLC, afatinib, giotrif

NICE is recommending that Boehringer Ingelheim’s first oncology treatment Giotrif be funded by the NHS. The new final draft guidance …

News
Sarah Edwards image

Breaking into the oncology market

March 10, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer, Cancer, NSCLC, edwards, gilotrif, oncology

In many ways, the US approval of Boehringer’s Gilotrif for patients with late-stage non-small cell lung cancer (NSCLC) last year …

Feature

Latest content

AstraZeneca’s Imfinzi approved in US for endometrial cancer treatment

June 17, 2024

Innate Pharma shares results from phase 1/2 trial for blood cancer treatment

June 17, 2024

CytoSorbents announces EU launch and availability of PuriFi blood pump

June 14, 2024

AbbVie and FutureGen announce license agreement for IBD therapy

June 14, 2024

Pfizer shares update on DMD gene therapy clinical trial

June 13, 2024